| Project/Area Number |
25670452
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KIMURA Shinya 佐賀大学, 医学部, 教授研究者 (80359794)
ARIMA Hidetoshi 熊本大学, 大学院生命科学研究部, 教授 (50260964)
IRIE Tetsumi 熊本大学, 大学院生命科学研究部, 教授 (60150546)
|
|---|
| Project Period (FY) |
2013-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | 血液腫瘍学 / 抗腫瘍薬 / コレステロール / 脂質ラフト / シクロデキストリン / 白血病 / アポトーシス / 細胞周期停止 / 悪性腫瘍 / 分子標的 / マウス移植モデル |
|---|
| Research Abstract |
We investigated anticancer activities of HP-b-CyD using BCR-ABL-induced leukemia models. We show that HP-b-CyD-mediated cholesterol efflux inhibits leukemic cell proliferation by induction of apoptosis and cell-cycle arrest. Furthermore, we found that HP-b-CyD is also effective to inhibit the proliferation of CML cells harboring the T315I mutation and stem cell-like CML cells. In vivo, systemic administration of HP-b-CyD in murine BCR-ABL-induced leukemia models suppressed leukemia progression, resulting in improved survival. Based on these novel findings, we provide evidence that HP-b-CyD is a promising anticancer agent.
|
